Clinical Study of Lithium Carbonate Combined with 131I for Treatment of Graves’Disease with Leucocytopenia
WEN Xiaoqin
OUYANG Liang
HU Jiankang
LU Xiaoxiao
ZHU Jingru
GAO Haibo
Abstract：Objective To explore the efficacy and clinical value of 131I combined with lithium carbonate in the treat-ment of Graves’disease with leucocytopenia. Methods Patients (n=348) were randomly divided into two groups. Experi-mental group (n=178) were treated with 131I plus lithium carbonate;Control group (n=170) were only treated with 131I. Recov-ery rate, effective rate, thyroid 131I uptake rate, the level of thyroid hormone (free triiodothyronine, FT3 and free thyroxine , FT4)and peripheral blood leukocyte were analyzed retrospectively. Results The recovery rate of the experimental group (87.6%)is significantly higher than that in the control group(71.8%). But the effective rate of the experimental group (97.8%)is not significantly different to that in the control group(94.1%). The 131I 24 h uptake rate in the experimental group(69.75±6.79)is higher than that in the control group(44.27±3.27)after the treatment of lithium carbonate. The level of thyroid hormone (FT3, FT4) in the experimental group are significantly lower than that before treatment after 2 weeks, 1 months. However, the levels of thyroid hormone (FT3, FT4) in the control group are higher than that before treatment after 2 weeks and began to decrease after 1 month. The treatment of experimental group contribute to the fast improvement of periph-eral blood leukocyte level. The level of peripheral blood leukocyte was significantly higher than that before treatment after 3 months(P<0.01). Conclusion The treatment of lithium carbonate combined with 131I for Graves’disease with leukope-nia is safe and effective.
Keywords：Graves diseaseleukopenialithium carbonateiodinetriiodothyroninethyroxine
Publication Date：2014-01-01